tradmap

KLRA Earnings Kailera Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Chart & overview → Latest filing

Quarterly results

Diluted EPS (quarterly)
-$28947 -$14474 $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$111M -$56M $0 Q1 '25 Q2 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-10% 4% 18% 0% Q1 '25 Q2 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–4 of 4
Q2 20262026-06-30-1.092026-08-1210-Q
Q1 20262026-03-31-3650.002026-05-2610-Q
Q2 20252025-06-30-28947.00——
Q1 20252025-03-31-17983.00——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.